Immunic, Inc. (IMUX)

NCM – Real Time Price. Currency in USD

16.14

+0.66 (4.26%)

Market open: Aug 12, 2026, 3:10 PM EDT

15.48

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and commercialization. The biotechnology company reported second-quarter results on Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis remain on track to deliver top-line data by the end of 2026.

11.08.2026

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Leadership Team Expanded with Key Executive Appointments, Including Chief Executive Officer, Chief Medical Officer and Chair of the Board of Directors, to Support Clinical Development, as well as NDA and Commercial Readiness – – Pivotal Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis on Track, with Top-Line Data Expected by End of 2026 – – Continued Preparations for Phase 3 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis, with Initiation Planned Later This Year – NEW YORK, Aug. 11, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. "During the second quarter, we continued to execute across our late-stage development priorities as we advance toward what we believe will be a transformational period for Immunic," said Erik Lundgren, Chief Executive Officer of Immunic.

10.08.2026

Immunic Appoints Elena Ridloff to Board of Directors

– Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in Relapsing Multiple Sclerosis as well as Potential Regulatory Filings and Commercialization – NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Elena Ridloff, CFA to its Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than two decades of experience driving financial strategy, corporate growth, and capital markets execution across the biopharmaceutical industry.

Videos

No Data

There is no data to display

Press releases

11.08.2026

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

10.08.2026

Immunic, Inc. (IMUX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunic, Inc. (IMUX)

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Videos

No Data

Press releases

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Videos

No Data

Press releases

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Search stocks

Immunic, Inc. (IMUX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunic, Inc. (IMUX)

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Videos

No Data

Press releases

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors

Videos

No Data

Press releases

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic Appoints Elena Ridloff to Board of Directors